Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

153.78 -0.27 (-0.18%)
Streaming Delayed Price Updated: 10:04 AM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
News headline image
Is the Market Bullish or Bearish on Novartis AG? ↗
 
Via Benzinga
News headline image
United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short ↗
Shares of United Therapeutics slipped slightly Wednesday on light sales of its bread-and-butter drug, Tyvaso. 
Via Investor's Business Daily
News headline image
Novartis Slips As Generics Champ At Heart-Failure Drug In Mixed Third Quarter ↗
Generic competition had a 7 percentage-point negative impact on the company's biggest drug. 
Via Investor's Business Daily
News headline image
Earnings Scheduled For October 28, 2025 ↗
 
Via Benzinga
News headline image
Novartis Maintains Outlook Even As Generics Bite Into Profits ↗
Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighed on results. 
Via Benzinga
News headline image
'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours ↗
U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acquisitions (M&A) are picking up after the tariff-induced cool-off earlier... 
Via Benzinga
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis ↗
Via Stocktwits
News headline image
What to Expect from Novartis's Earnings ↗
 
Via Benzinga
News headline image
Is It Too Late To Buy Avidity Stock After Novartis Deal? ↗
Novartis revealed plans of acquiring Avidity Biosciences Inc. in a $12 billion all-cash transaction. The announcement sent RNA shares soaring roughly 44% on Monday. 
Via Talk Markets
News headline image
Why Dyne Therapeutics Stock Crushed the Market on Monday ↗
Biotechs like it are clearly valuable to strategic acquirers. 
Via The Motley Fool
News headline image
Wall Street Soars as Qualcomm Ignites the AI Race ↗
Investor optimism drives the S&P 500 to new records while Qualcomm steals the spotlight with an 11% surge after unveiling new AI chips. 
Via Chartmill
Topics Artificial Intelligence Stocks
News headline image
Why Avidity Biosciences Stock Blasted 42% Higher Today ↗
If all goes well, the company will be part of a much larger enterprise starting next year. 
Via The Motley Fool
News headline image
Avidity Biosciences Soars After $72 Per Share Novartis Takeover ↗
Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral. 
Via Benzinga
News headline image
Qualcomm, Tesla, Intellia Therapeutics, Avidity Biosciences, Dyne Therapeutics: Stocks Making The Biggest Moves Today ↗
Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Via Investor Brand Network
News headline image
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal ↗
Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash. 
Via Benzinga
News headline image
Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today ↗
Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share. 
Via Stocktwits
News headline image
Stock Market Today: Dow Jones, S&P 500 Futures Climb Ahead Of Busy Week On Wall Street—Novartis, Nucor, Waste Management In Focus ↗
U.S. stock futures rose on Monday following Friday’s positive moves. Futures of major benchmark indices were higher. 
Via Benzinga
Topics Stocks
News headline image
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly... 
Via MarketMinute
News headline image
Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock ↗
Kratos secured a $68.3 million deal and a contract through the Defense Department's Industrial Base Analysis and Sustainment Program. 
Via Benzinga
News headline image
AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare
The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence
News headline image
Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain ↗
Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing significant sustained remission. 
Via Benzinga
News headline image
Novartis AG-Sponsored ADR (NYSE:NVS): A Pillar of Dividend Reliability and Financial Health ↗
Novartis (NVS) offers a strong 3.35% dividend yield with a history of steady growth, backed by robust profitability and sound financial health for reliable income. 
Via Chartmill
News headline image
Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial ↗
Novartis' five-year NATALEE trial shows Kisqali plus endocrine therapy reduces recurrence risk and improves breast cancer survival. 
Via Benzinga
News headline image
Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug ↗
Eli Lilly said Friday a combo using Verzenio cut the risk of death by nearly 16% over two years for breast cancer patients. 
Via Investor's Business Daily
News headline image
AI: The Medical Maverick – Navigating Hype and Hope in Healthcare’s Digital Revolution
Artificial intelligence (AI) stands at the precipice of a profound transformation in healthcare, promising a future where diagnostics are sharper, treatments are more personalized, and patient care is... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
News headline image
Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗
Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.